Table 2

Impact of NAI therapy starting at 48 h postinfection in mice infected with a recombinant A/WSN/33 (H1N1) WT virusa

Regimen% mortality on day 12 p.i. (n = 8)Mean % wt loss ± SD on day 5 p.i. (n = 11–12)Mean lung viral titer (PFU/ml) ± SD on day 5 p.i. (n = 4)
Uninfected/untreated0***−2.8 ± 0.7***Nd
Untreated-infected10020.4 ± 1.11.6 × 106 ± 0.6 × 106
Oseltamivir 5 × 1 mg/kg0***5.3 ± 0.8***6.6 × 101 ± 6.4 × 101***
Oseltamivir 5 × 10 mg/kg0***4.4 ± 1***8.6 × 101 ± 4.6 × 101***
Peramivir 1 × 90 mg/kg0***1.5 ± 0.7***2 × 101 ± 0***
Peramivir 5 × 45 mg/kg0***2 ± 0.8***2 × 101 ± 0***
  • a ***, P < 0.001 versus the untreated group. Statistical significance was determined by using Kaplan Meier analysis for mortality and the one-way ANOVA test for weight loss and lung viral titers. Nd, not determined. The viral inoculum was 8 × 103 PFU.